MEI Pharma Inc. | Key People and Executives
Daniel P. Gold
President, Chief Executive Officer & Director
Frederick W. Driscoll
Non-Executive Director
Christine Anna White
Non-Executive Chairman
Kevan E. Clemens
Independent Non-Executive Director
Nicholas R. Glover
Independent Non-Executive Director
Thomas C. Reynolds
Independent Non-Executive Director
Charles V. Baltic
Independent Non-Executive Director
William Dodge Rueckert
Independent Non-Executive Director
Daniel P. Gold
President, Chief Executive Officer & Director
David M. Urso
COO, SVP-Corporate Development & General Counsel
Brian G. Drazba
CFO, Secretary & Principal Accounting Officer
Richard G. Ghalie
Senior Vice President-Clinical Development
Robert D. Mass
Chief Medical Officer
Ofir Moreno
Vice President-Research & Development
Frederick W. Driscoll
Non-Executive Director
David A. Walsey
VP-Investor Relations & Corporate Communications
Karen E. Potts
Senior Vice President-Regulatory Affairs
Christine Anna White
Non-Executive Chairman
Kevan E. Clemens
Independent Non-Executive Director
Nicholas R. Glover
Independent Non-Executive Director
Thomas C. Reynolds
Independent Non-Executive Director
Charles V. Baltic
Independent Non-Executive Director
William Dodge Rueckert
Independent Non-Executive Director
| Address |
3611 Valley Centre Drive
San Diego California 92130
United States
|
|
Employees
|
- |
| Website |
http://www.meipharma.com |
| Updated |
07/08/2019 |
| MEI Pharma, Inc. engages in the clinical development of novel therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, a highly selective, oral PI3K delta inhibitor; voruciclib, an oral, selective CDK inhibitor; and ME-344, a novel mitochondrial inhibitor. |
